Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gliadel and Temozolomide in Newly Diagnosed Malignant Glioma
NCT00283543Phase 2Unknown
- Sponsor
- Kentuckiana Cancer Institute
- Start
- Sep 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of carmustine in malignant glioma, sponsored by Kentuckiana Cancer Institute. Status: unknown.
02
Drugs
carmustine
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00283543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00283543.